Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;15(6):733-741.
doi: 10.1007/s11523-020-00753-7.

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie G Fisher  1 , David Tait  1 , Elizabeth Garrett-Mayer  2 , Susan Halabi  3 , Pam K Mangat  4 , Julian C Schink  5 , Ricardo H Alvarez  6 , Dan Veljovich  7 , Timothy L Cannon  8 , Pamela A Crilley  9 , Theodore Pollock  10 , Carmen J Calfa  11 , Tareq Al Baghdadi  12 , Ramya Thota  13 , Nicole Fleming  14 , Jared A Cotta  11 , Andrew L Rygiel  2 , Sasha L Warren  2 , Richard L Schilsky  2
Affiliations

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie G Fisher et al. Target Oncol. 2020 Dec.

Abstract

Background: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets.

Objective: With no known genomic targets predictive of sensitivity to cetuximab, cetuximab was evaluated in patients with breast cancer (BC), non-small cell lung cancer (NSCLC), and ovarian cancer (OC), without KRAS, NRAS, or BRAF mutations.

Patients and methods: Eligible patients with advanced BC, NSCLC, and OC received a cetuximab loading dose, then weekly infusions (250 mg/m2 over 60 min). A Simon two-stage design, requiring ten patients in stage I, was employed per each disease-specific cohort. The primary endpoint was disease control (objective response or stable disease for at least 16 weeks). If two or more patients in stage I achieved disease control, the cohort would enroll 18 more patients in stage II. Power and alpha of the design are 85% and 10%, respectively. Secondary endpoints included progression-free survival, overall survival, and safety.

Results: Patients with BC (n = 10), NSCLC (n = 10), and OC (n = 29) were enrolled between June 2016 and September 2018. No objective responses or stable disease for at least 16 weeks were observed in the BC and NSCLC cohorts. No objective responses and four patients with stable disease for at least 16 weeks were observed in the OC cohort. Six of 49 patients reported grade 3 or higher adverse events or serious adverse events at least possibly related to cetuximab.

Conclusions: Cetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC without KRAS, NRAS, or BRAF mutations.

Clinical trial registration: NCT02693535 (26 February, 2016).

PubMed Disclaimer

References

    1. Myers MB, Banda M, McKim KL, Wang Y, Powell MJ, Parsons BL. Breast cancer heterogeneity examined by high-sensitivity quantification of PIK3CA, KRAS, HRAS, and BRAF mutations in normal breast and ductal carcinomas. Neoplasia. 2016;18(4):253–63. https://doi.org/10.1016/j.neo.2016.03.002 . - DOI - PubMed - PMC
    1. Madhusudanannair V, Janku F, Falchook GS, Hong DS, Wheler JJ, Naing A, et al. NRAS mutations in patients with advanced cancers treated with target-based therapies in early-phase clinical trials. J Clin Oncol. 2012;30(15_Suppl.):3106. https://doi.org/10.1200/jco.2012.30.15_suppl.3106 . - DOI
    1. Jung YY, Jung WH, Koo JS. BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody. Int J Clin Exp Pathol. 2016;9(2):1545–56.
    1. Bustamante JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs Context. 2019;8:1–5. https://doi.org/10.7573/dic.212566 . - DOI
    1. Wood K, Hensing T, Malik R, Salgia R. Prognostic and predictive value in KRAS in non-small-cell lung cancer. JAMA Oncol. 2016;2(6):805. https://doi.org/10.1001/jamaoncol.2016.0405 . - DOI - PubMed

Publication types

Substances

Associated data